A hemangioblastoma in a patient with von Hippel-Lindau disease showed somatostatin receptor expression on peptide-receptor imaging, and one year of lanreotide treatment decreased radiotracer uptake — suggesting somatostatin receptors as a new therapeutic target for these currently untreatable tumors.
Metabolic response after 1 year of lanreotide68Ga-DOTATOC PET showed decreased somatostatin receptor activity in the hemangioblastoma after somatostatin analog therapy — a first for a tumor type with no approved systemic treatments
What the researchers found
Peptide-receptor radionuclide imaging with 68Ga-DOTATOC identified increased somatostatin receptor expression in a suprasellar hemangioblastoma in a VHL patient. The same scan revealed multiple pancreatic neuroendocrine tumors and bilateral pheochromocytomas.
After one year of treatment with lanreotide (a somatostatin analog), repeat 68Ga-DOTATOC imaging showed decreased radiotracer uptake by the hemangioblastoma, consistent with a metabolic response. This is significant because no systemic therapy has previously shown a response in VHL-associated hemangioblastomas, and somatostatin receptor expression in these tumors had only recently been reported in the literature.
Why it matters
VHL disease affects approximately 1 in 36,000 people, and hemangioblastomas are among its most debilitating manifestations — they can occur in the brain, spinal cord, and retina. Surgery is currently the only option, but tumors frequently recur and multiply over time. The discovery that these tumors express somatostatin receptors opens three opportunities: using peptide-receptor imaging for better diagnosis and monitoring, treating with somatostatin analogs like lanreotide (already FDA-approved), and potentially using peptide receptor radionuclide therapy (PRRT) for more aggressive disease.
How the study worked
This is a single case report with literature review. The patient underwent MRI for tumor detection and 68Ga-DOTATOC PET/CT for somatostatin receptor imaging before and after 12 months of lanreotide therapy. Treatment response was assessed by comparing radiotracer uptake between baseline and follow-up imaging.
What this study cannot tell us
This is a single case report — the lowest level of clinical evidence. Decreased radiotracer uptake suggests metabolic response but doesn't necessarily mean tumor shrinkage or clinical benefit. No imaging measurement of tumor size change was reported. One year of follow-up is short for a chronic condition like VHL. The response may not be generalizable to other VHL patients or hemangioblastomas in different locations. The concurrent presence of neuroendocrine tumors made this patient an unusual case.
How to read the evidence
This is a single case report with objective imaging evidence (68Ga-DOTATOC PET before and after treatment). While the imaging response is well-documented, the lowest tier of clinical evidence cannot establish treatment efficacy. It serves primarily as hypothesis-generating evidence for future studies.
When this study was published
Published in 2024, this is a very recent case report reflecting current peptide-receptor imaging and somatostatin analog therapy approaches.
The bigger picture
Somatostatin receptor-targeted therapies have transformed the treatment of neuroendocrine tumors, with 177Lu-DOTATATE (Lutathera) as the landmark example. Extending this approach to hemangioblastomas — which were not previously known to express somatostatin receptors — could open an entirely new treatment paradigm for VHL disease. The fact that these patients often have concurrent neuroendocrine tumors (also somatostatin receptor-positive) means a single peptide-targeted therapy could potentially address multiple tumor types simultaneously.
Questions still open
- Do all VHL-associated hemangioblastomas express somatostatin receptors, or is this limited to certain subtypes or locations?
- Would peptide receptor radionuclide therapy (177Lu-DOTATATE) provide a stronger antitumor response than somatostatin analog therapy alone?
- Could routine 68Ga-DOTATOC imaging improve surveillance and early detection of hemangioblastomas in VHL patients?
Common questions
What is von Hippel-Lindau disease and why are hemangioblastomas hard to treat?
How does the 68Ga-DOTATOC scan work?
Read the original research
Expression of somatostatin receptors in hemangioblastomas associated with von Hippel-Lindau disease as a novel diagnostic, therapeutic, and follow-up opportunity: A case report and literature review.
Archives of endocrinology and metabolism, 68, e230181
Citation
Brabo, Eloá Pereira; de Almeida, Sergio Altino; Rafful, Patrícia Piazza; Rosado-de-Castro, Paulo Henrique; Vieira Neto, Leonardo. (2024). Expression of somatostatin receptors in hemangioblastomas associated with von Hippel-Lindau disease as a novel diagnostic, therapeutic, and follow-up opportunity: A case report and literature review.. Archives of endocrinology and metabolism, 68, e230181. https://doi.org/10.20945/2359-4292-2023-0181